208 related articles for article (PubMed ID: 33853558)
1. Humanized anti-DEspR IgG4
Gromisch CM; Tan GLA; Pasion KA; Moran AM; Gromisch MS; Grinstaff MW; Carr FJ; Herrera VLM; Ruiz-Opazo N
BMC Cancer; 2021 Apr; 21(1):407. PubMed ID: 33853558
[TBL] [Abstract][Full Text] [Related]
2. DEspR roles in tumor vasculo-angiogenesis, invasiveness, CSC-survival and anoikis resistance: a 'common receptor coordinator' paradigm.
Herrera VL; Decano JL; Tan GA; Moran AM; Pasion KA; Matsubara Y; Ruiz-Opazo N
PLoS One; 2014; 9(1):e85821. PubMed ID: 24465725
[TBL] [Abstract][Full Text] [Related]
3. Concomitant targeting of multiple key transcription factors effectively disrupts cancer stem cells enriched in side population of human pancreatic cancer cells.
Wang X; Liu Q; Hou B; Zhang W; Yan M; Jia H; Li H; Yan D; Zheng F; Ding W; Yi C; Hai Wang
PLoS One; 2013; 8(9):e73942. PubMed ID: 24040121
[TBL] [Abstract][Full Text] [Related]
4. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
5. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
6. Confirmation of translatability and functionality certifies the dual endothelin1/VEGFsp receptor (DEspR) protein.
Herrera VL; Steffen M; Moran AM; Tan GA; Pasion KA; Rivera K; Pappin DJ; Ruiz-Opazo N
BMC Mol Biol; 2016 Jun; 17(1):15. PubMed ID: 27301377
[TBL] [Abstract][Full Text] [Related]
7. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
[TBL] [Abstract][Full Text] [Related]
8. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
[TBL] [Abstract][Full Text] [Related]
9. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
Ying J; Tsujii M; Kondo J; Hayashi Y; Kato M; Akasaka T; Inoue T; Shiraishi E; Inoue T; Hiyama S; Tsujii Y; Maekawa A; Kawai S; Fujinaga T; Araki M; Shinzaki S; Watabe K; Nishida T; Iijima H; Takehara T
Int J Oncol; 2015 Apr; 46(4):1551-9. PubMed ID: 25625841
[TBL] [Abstract][Full Text] [Related]
11. JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells.
Recio-Boiles A; Ilmer M; Rhea PR; Kettlun C; Heinemann ML; Ruetering J; Vykoukal J; Alt E
Oncotarget; 2016 Mar; 7(9):9890-906. PubMed ID: 26840266
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Matrix Composition Modulates the Responsiveness of Differentiated and Stem Pancreatic Cancer Cells to Lipophilic Derivate of Gemcitabine.
Forciniti S; Dalla Pozza E; Greco MR; Amaral Carvalho TM; Rolando B; Ambrosini G; Carmona-Carmona CA; Pacchiana R; Di Molfetta D; Donadelli M; Arpicco S; Palmieri M; Reshkin SJ; Dando I; Cardone RA
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375106
[TBL] [Abstract][Full Text] [Related]
13. Polyphenols from marine brown algae target radiotherapy-coordinated EMT and stemness-maintenance in residual pancreatic cancer.
Aravindan S; Ramraj SK; Somasundaram ST; Herman TS; Aravindan N
Stem Cell Res Ther; 2015 Sep; 6(1):182. PubMed ID: 26395574
[TBL] [Abstract][Full Text] [Related]
14. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
15. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
Cioffi M; Dorado J; Baeuerle PA; Heeschen C
Clin Cancer Res; 2012 Jan; 18(2):465-74. PubMed ID: 22096026
[TBL] [Abstract][Full Text] [Related]
16. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
[TBL] [Abstract][Full Text] [Related]
17. Anti-DEspR antibody treatment improves survival and reduces neurologic deficits in a hypertensive, spontaneous intracerebral hemorrhage (hsICH) rat model.
Herrera VLM; Gromisch CM; Decano JL; Pasion KA; Tan GLA; Hua N; Takahashi CE; Greer DM; Ruiz-Opazo N
Sci Rep; 2023 Feb; 13(1):2703. PubMed ID: 36792616
[TBL] [Abstract][Full Text] [Related]
18. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
20. Bulk pancreatic cancer cells can convert into cancer stem cells(CSCs) in vitro and 2 compounds can target these CSCs.
Ning X; Du Y; Ben Q; Huang L; He X; Gong Y; Gao J; Wu H; Man X; Jin J; Xu M; Li Z
Cell Cycle; 2016; 15(3):403-12. PubMed ID: 26709750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
